Clinical trial
Glitazones and Endothelial Function (GATE)
NCT00203632 · University of Calgary, Other · Terminated
Key facts
| NCT number | NCT00203632 |
|---|---|
| Title | Glitazones and Endothelial Function (GATE) |
| Official title | A Trial of the Effect of Rosiglitazone as Add on to Metformin Therapy on Endothelial Function in Subjects With Type II DM |
| Lead sponsor | University of Calgary, Other |
| Collaborators | GlaxoSmithKline Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | rosiglitazone/placebo |
| Enrollment | 40 |
| Start date | Sep 1, 2003 |
| Completion | Oct 1, 2007 |
| First posted | Sep 20, 2005 |
| Last update posted | Nov 3, 2008 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: